Services on Demand
- Cited by SciELO
- Access statistics
Revista Brasileira de Hematologia e Hemoterapia
Print version ISSN 1516-8484On-line version ISSN 1806-0870
MASSUMOTO, Celso M. et al. Gemtuzumab Ozogamicin: an option in the treatment of acute myeloid leukemia CD33+. Rev. Bras. Hematol. Hemoter. [online]. 2004, vol.26, n.4, pp.235-238. ISSN 1516-8484. http://dx.doi.org/10.1590/S1516-84842004000400002.
Gemtuzumab Ozogamicin consists of a semisynthetic derivate of calicheamicin, a cytotoxic antibiotic linked to a recombinant monoclonal antibody directed against the CD33 antigen present on leukemic myeloblasts. The aim of this report is to evaluate the side effects, remission and survival of 11 patients with acute myeloid leukemia that took Gemtuzumab Ozogamicin. The major toxicity was myelosuppression that was seen in all the patients. One patient died due to hepatic veno-occlusive disease. Four patients used the drug for relapse and two achieved partial remission. Two patients used the drug for refractory disease and one achieved complete remission with 12 months survival. Gemtuzumab Ozogamicin was also used for the consolidation therapy of 5 patients. We believe that Gemtuzumab Ozogamicin is safe and is an alternative for patients that do not respond to conventional therapy.
Keywords : Gemtuzumab Ozogamicin; leukemia; therapy.